See more : Carimin Petroleum Berhad (5257.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Galp Energia, SGPS, S.A. (GLPEF) Income Statement Analysis – Financial Results
- Koninklijke DSM N.V. (RDSMY) Income Statement Analysis – Financial Results
- Sparinvest INDEX Europa Value KL (SPIEUVKL.CO) Income Statement Analysis – Financial Results
- Sumit Woods Limited (SUMIT.NS) Income Statement Analysis – Financial Results
- Electricité de France S.A. (ECIFY) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
Calyxt Announces Expansion of Hemp Breeding Platform with Seedless Hemp Innovation
Triploid Breeding Process is Calyxt's Second Announced Advancement and Part of a Comprehensive Approach to Improving Hemp Genetics ROSEVILLE, MN / ACCESSWIRE / July 8, 2021 / Calyxt, Inc. (NASDAQ:CLXT), today announced further expansion of its hemp breeding platform with...
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared...
Calyxt: Proprietary TALEN Plant-Technology Offers Multi-Industry Growth
Calyxt is a plant-technology company that develops plant-based innovations and solutions aiming to disrupt a broad group of industries. Calyxt is a leading gene-editor with exclusive access to the parent company's proprietary TALEN technology for use in plants which resulted...
Calyxt, Inc. (CLXT) Q1 2021 Results - Earnings Call Transcript
Calyxt, Inc. (CLXT) Q1 2021 Results - Earnings Call Transcript
Calyxt Announces Next Generation Premium Soybean Product Line Performance Best-In-Class for High Oleic, Ultra-Low Linolenic Profile
Next Generation Premium Soybean Product Line Contains Ultra-Low Levels of Linolenic Acid Positioning it to be the Most Stable Premium Soybean Oil Available on the Market R&D Advancement with Complex Plant Biological Pathways Enables Calyxt to Deliver Next Generation Plant-Based...
Calyxt Successfully Transforms Hemp Genome
New Hemp Transformation Technology Unlocks Capabilities to Selectively Breed and Deliver Improvements in Hemp Traits for Key Markets Including Protein, Fiber, Advanced Materials and Wellness Patent-Pending Transformation Process is Calyxt's First Announced Innovation in a Broad Hemp Improvement Pipeline ROSEVILLE,...
Calyxt to Present at Upcoming Investor and Industry Conferences
ROSEVILLE, MN / ACCESSWIRE / April 20, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor and industry conferences during the month of May 2021: 2021 American Oil Chemists Society (AOCS) Annual Meeting...
Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time
Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, Ma y 6 , 202 1 at 4 :30 p .m. Eastern Time ROSEVILLE, MN / ACCESSWIRE / April 15, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology...
Calyxt Using A More Conventional Model To Pursue Significant New Agri-Bio Market Opportunities
Calyxt has changed its operating strategy to a more conventional agri-bio seed/trait model similar to those pursued by established agri-bio names like Bayer and Corteva. Calyxt is targeting new high-risk/high-reward market opportunities including winter oats, hemp, and soybeans with saturated...
Calyxt, Inc. (CLXT) Q4 2020 Results - Earnings Call Transcript
Calyxt, Inc. (CLXT) Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports